GLP-1 (Glucagon-Like Peptide-1) is a 30-amino acid incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Its primary physiological roles include stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and — critically for obesity research — reducing food intake through central appetite suppression via GLP-1 receptors in the hypothalamus and brainstem.

The GLP-1 receptor agonist class has produced the most significant weight loss outcomes in the history of obesity pharmacology. The clinical evidence arc runs from liraglutide (Saxenda — approximately 5-8% mean weight loss in Phase 3 trials), to semaglutide (Ozempic/Wegovy — 14.9% mean weight loss at 68 weeks in the STEP 1 trial, NEJM 2021), to tirzepatide (Mounjaro/Zepbound — 20.9% mean weight loss at 72 weeks in SURMOUNT-1, NEJM 2022), to the emerging triple-agonist class.

Mechanistically, the progression from liraglutide to tirzepatide reflects the addition of receptor targets: semaglutide is a selective GLP-1R agonist, while tirzepatide is a dual GLP-1R/GIPR (glucose-dependent insulinotropic polypeptide receptor) agonist. The GIP receptor appears to synergize with GLP-1 receptor activation for weight reduction, explaining tirzepatide's superior efficacy.

Retatrutide (LY3437943) is a triple GLP-1R/GIPR/GcgR agonist developed by Eli Lilly — the first clinical-stage compound to add glucagon receptor (GcgR) agonism to the GLP-1/GIP combination. Glucagon receptor activation in the context of a GLP-1/GIP background is hypothesized to increase energy expenditure (through thermogenesis and hepatic fat mobilization) without the hyperglycemia that isolated glucagon agonism would cause.

The landmark Phase 2 trial data for Retatrutide was published in the New England Journal of Medicine in 2023 (Jastreboff et al., 2023). Key findings:

These outcomes established Retatrutide as the leading clinical candidate for obesity pharmacotherapy in 2023, surpassing the weight reduction benchmarks set by tirzepatide. Phase 3 trials are ongoing.

For research purposes, Retatrutide's triple-agonism mechanism makes it valuable for studying the incremental contribution of GcgR activation to metabolic outcomes — a scientifically important question given the controversial role of glucagon in obesity pathophysiology.

MOTS-c approaches metabolic regulation from a fundamentally different direction than the GLP-1 class. Rather than modulating gut-brain appetite signaling, MOTS-c acts as an intracellular metabolic regulator through AMPK activation and nuclear gene expression control.

MOTS-c was first described in the context of insulin resistance research (Lee et al., 2015, *Cell Metabolism*). The primary findings included: MOTS-c treatment improved insulin sensitivity in high-fat diet mice, reduced adipose tissue accumulation, and activated AMPK in skeletal muscle — the same pathway activated by exercise and metformin. Subsequent research demonstrated that MOTS-c levels are lower in obese and insulin-resistant subjects compared to metabolically healthy controls, suggesting it functions as an endogenous metabolic regulator.

For weight and metabolic research, MOTS-c's most relevant published effects include:

Adipogenesis inhibition: MOTS-c reduces differentiation of preadipocytes into mature adipocytes in cell culture models, providing a mechanism for its anti-adiposity effects.

Glucose utilization: MOTS-c activates the AMPK pathway that drives glucose uptake in skeletal muscle, improving glucose disposal independent of insulin — relevant to research on insulin resistance and type 2 diabetes models.

Exercise-like transcriptional effects: MOTS-c activates many of the same nuclear gene expression programs as aerobic exercise (through AMPK-PGC1α signaling), leading to it being described as an "exercise mimetic" in published research.

MOTS-c represents a mechanistically distinct alternative to the GLP-1 class for metabolic research — targeting intracellular energy sensing rather than gut-brain hormone signaling.

For researchers studying metabolic interventions, understanding the comparative evidence for each compound is essential context:

Semaglutide (GLP-1R agonist only): STEP 1 trial (NEJM 2021) — 14.9% mean weight loss at 68 weeks. Best-in-class for single-receptor GLP-1 agonism. Now generic understanding of GLP-1 pharmacology.

Tirzepatide (GLP-1R + GIPR dual agonist): SURMOUNT-1 trial (NEJM 2022) — 20.9% mean weight loss at 72 weeks. Demonstrated that dual agonism produces superadditive weight loss vs. GLP-1 alone. FDA approved for obesity (Zepbound).

Retatrutide (GLP-1R + GIPR + GcgR triple agonist): Phase 2 trial (NEJM 2023) — 24.2% mean weight loss at 48 weeks. Highest clinical weight loss data published to date (at a shorter time point than tirzepatide Phase 3). Phase 3 ongoing.

The mechanistic progression — adding GIP → adding glucagon → potentially adding additional targets — represents an active research question about the ceiling of pharmacological weight loss and the role of each receptor in the metabolic response.

MOTS-c is not directly comparable to the GLP-1 class in efficacy terms (no human weight loss RCT data yet), but represents an entirely distinct mechanistic approach with potential complementarity — AMPK-mediated metabolic programming rather than appetite suppression.

The metabolic peptide research landscape has significant clinical translation implications, but the regulatory and ethical context is important for researchers:

Semaglutide and tirzepatide are FDA-approved drugs — they are prescription pharmaceuticals with established safety profiles from large Phase 3 trials. Research use of these approved agents requires standard clinical trial or observational study frameworks.

Retatrutide is in active Phase 3 clinical trials — it is not approved and is available only through clinical trial participation.

MOTS-c is an investigational research compound with no IND or NDA filing. It is available for research purposes through specialized research chemical suppliers and is studied in preclinical models under research-use frameworks.

For researchers designing metabolic studies, the distinction matters: GLP-1 class agents are validated pharmaceuticals being studied in approved clinical frameworks, while MOTS-c and related mitokines are in earlier-stage preclinical research with different regulatory considerations. The mechanistic questions they address are complementary, and combination preclinical research (GLP-1 agonist + AMPK activator) represents an emerging frontier.

All compounds described in the context of preclinical and early clinical research are available for research purposes only. They are not approved for weight loss use outside of appropriate clinical trial or prescription contexts.